Company Overview and News

19
BDSI / BioDelivery Sciences International, Inc. PRE 14A

2018-06-20 sec.gov
PRE 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the
BDSI

5
BioDelivery Sciences (BDSI) Presents At William Blair 2018 Growth Stock Conference - Slideshow

2018-06-15 seekingalpha
The following slide deck was published by BioDelivery Sciences International, Inc. in conjunction with this event.
BDSI

58
Endo International (ENDP) Up 12.4% Since Earnings Report: Can It Continue?

2018-06-07 zacks
It has been about a month since the last earnings report for Endo International plc (ENDP - Free Report) . Shares have added about 12.4% in that time frame.
CORT ENL BDSI CRAI ENDP

5
BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference

2018-05-23 globenewswire
RALEIGH, N.C., May 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Herm Cukier, Chief Executive Officer, and Scott Plesha, President will present at the Jefferies 2018 Global Healthcare Conference taking place at the Grand Hyatt in New York, NY.
BDSI

8
BDSI / BioDelivery Sciences International, Inc. FORM 8-K (Current Report)

2018-05-22 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BDSI

50
BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board

2018-05-22 globenewswire
RALEIGH, N.C., May 22, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct offering of newly designated Series B Non-Voting Convertible Preferred Stock. The offering closed on May 21, 2018, yielding net proceeds of $48.9 million to BDSI.
CERC SCMP BDSI

5
BDSI / BioDelivery Sciences International, Inc. / Broadfin Capital, LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13D (Activist Investment)

2018-05-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101)
BDSI

6
BDSI / BioDelivery Sciences International, Inc. / Broadfin Capital, LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13D (Activist Investment)

2018-05-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101)
BDSI

10
BDSI / BioDelivery Sciences International, Inc. FORM 8-K (Current Report)

2018-05-21 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BDSI

7
BDSI / BioDelivery Sciences International, Inc. 424B3 (Prospectus)

2018-05-17 sec.gov
424B3 Table of Contents Prospectus Supplement Filed Pursuant to Rule 424(b)(3) (to P
BDSI

6
BDSI / BioDelivery Sciences International, Inc. FWP

2018-05-17 sec.gov
FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 17, 2018 Relating to the Prospectus dated July 13, 2015 Registration No 333-205483
BDSI

6
BDSI / BioDelivery Sciences International, Inc. FORM 8-K (Current Report)

2018-05-17 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BDSI

14
BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business

2018-05-17 globenewswire
RALEIGH, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into an agreement with an affiliate of Broadfin Capital LLC (Broadfin), a large BDSI stockholder, to reconstitute BDSI’s Board of Directors and to significantly strengthen BDSI’s financial position. The closing of this agreement is subject to and effective upon the closing of BDSI’s $50 million equity financing announced earlier today.
MNK SCMP BDSI

5
BioDelivery Sciences Announces Pricing of $50 Million Equity Financing

2018-05-17 globenewswire
RALEIGH, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into definitive agreements with existing institutional and other accredited investors to purchase an aggregate of approximately $50 million worth of BDSI’s newly designated Series B Non-Voting Convertible Preferred Stock (Series B Stock) in a registered direct offering.
BDSI

10
BDSI / BioDelivery Sciences International, Inc. FORM 8-K (Current Report)

2018-05-11 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BDSI

Related Articles

HIMX: Himax Technologies Analysis and Research Report

13h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

CUSIP: 09060J106